絞り込み

16645

広告

新型肺炎 中国国内の死者82人 北京で50歳の男性死亡

中国で感染が拡大している新型のコロナウイルスについて、北京市の保健当局は27日、新たに50歳の男性が死亡したと発表しました。北京市で死者が確認されたのは初めてで...

  1. 新型肺炎 中国本土以外で確認された感染者...
  2. 新型肺炎 カンボジアで初の感染者を確認 ...
  3. 【材料科学】核廃棄物貯蔵容器内の材料界面...
  4. iPS初の心筋移植「一人でも多くの患者が...

ニュース一覧

New drugs creating new challenges in acute myeloid leukemia.

著者 Tiong IS , Wei AH
Genes Chromosomes Cancer.2019 Mar 12 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (9view , 0users)

Full Text Sources

Miscellaneous

The therapeutic landscape is rapidly changing, with 8 new drugs approved by the Food and Drug Administration within the last 2 years, including midostaurin and gilteritinib for FLT3 mutant newly diagnosed and relapsed/refractory (R/R) acute myeloid leukemia (AML), respectively; CPX-351 (liposomal cytarabine and daunorubicin) for therapy-related AML and AML with myelodysplasia-related changes; gemtuzumab ozogamicin (anti-CD33 monoclonal antibody conjugated with calicheamicin) for newly diagnosed and R/R CD33-positive AML; enasidenib and ivosidenib for IDH2 and IDH1 mutant R/R AML, respectively. Novel therapies have also emerged for newly diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. These include venetoclax (BCL-2 inhibitor) in combination with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine (LDAC), and glasdegib (sonic hedgehog pathway inhibitor) in combination with LDAC. This flurry of new drug approvals has markedly altered the treatment landscape in AML and provided new opportunities, as well as new challenges for treating clinicians. This review will focus on how these drugs might shape clinical practice and the hurdles likely to be faced by new therapies seeking entry into this dynamic and rapidly changing therapeutic landscape. This article is protected by copyright. All rights reserved.
PMID: 30861214 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード